Literature DB >> 18415417

[Patient-controlled analgesia with subcutaneous opoids for out-patients with severe tumour pain.].

H Goeke1, M Herbst.   

Abstract

PCAO (patient-controlled analgesia in outpatients) is a new treatment concept designed to overcome chronic or acute pain of cancer patients. From 1989 to 1992, a total of with tumour pain 204 patients were treated in the pain clinics of Fürth in cooperation with the Department of Radiation at the University Hospital in Regensburg. In 90 of these patients adequate oral medication was impossible because of problems in swallowing or blockage of the gastrointestinal tract, and subcutaneous opioid infusion over 24 h was therefore instituted. The evaluation refers to 2311 days of treatment. While in 1989/90 only 35% (34/97) received subcutaneous opioid infusion, the proportion had already risen to 64% (54/84) by 1991/92. The proportion of patients who has to be treated as in-patients also fell: 26% in 1989/90, as against 10% in 1991/92. The subcutaneous infusion was well tolerated and accepted by the patients. In only 0.6% of cases was discontinuation necessitated by technical problems. Continuous subcutaneous applications of opioids is a highly effective therapeutic method with low risk and few side-effects. With the Perfusor M, the nurses and the patients can be trained to use the equipment. The patients can then administer boli themlselves when their pain is inadequately controlled. PCAO for treatment of cancer patients at home yields freedom from of pain around the clock, independence, and quality of life with active personal involvement. The most important thing is that the patient can sleep during the night, as can the doctor, the nurse and relatives, as they do not need to give injections during the night. This new method of treating the pain of cancer patients at home in advanced disease is also well accepted by social security authorities, as it reduces the costs dramatically.

Entities:  

Year:  1993        PMID: 18415417     DOI: 10.1007/BF02527636

Source DB:  PubMed          Journal:  Schmerz        ISSN: 0932-433X            Impact factor:   1.107


  28 in total

1.  PCA and cancer pain.

Authors:  J Devulder
Journal:  Acta Anaesthesiol Belg       Date:  1992

Review 2.  Treatment of the patient with cancer using parenteral electronic drug administration.

Authors:  H L Shaw
Journal:  Cancer       Date:  1992-08-15       Impact factor: 6.860

Review 3.  The role of patient-controlled analgesia in the management of cancer pain.

Authors:  B R Ferrell; C C Nash; C Warfield
Journal:  J Pain Symptom Manage       Date:  1992-04       Impact factor: 3.612

Review 4.  [Principles of pharmacotherapy in tumor-induced pain syndromes].

Authors:  W Schoon; U R Kleeberg
Journal:  Med Klin (Munich)       Date:  1987-11-13

Review 5.  The treatment of cancer pain.

Authors:  K M Foley
Journal:  N Engl J Med       Date:  1985-07-11       Impact factor: 91.245

6.  [Use of oral morphine in incurable pain].

Authors:  R Twycross; M Zenz
Journal:  Anaesthesist       Date:  1983-06       Impact factor: 1.041

7.  Professional and ethical considerations in the use of high-tech pain management.

Authors:  M Whedon; B R Ferrell
Journal:  Oncol Nurs Forum       Date:  1991 Sep-Oct       Impact factor: 2.172

8.  [Intractable cancer pain as a reason for referral : Analysis of pain etiology and previous drug treatment.].

Authors:  S Grond; D Zech; H Dahlmann; S A Schug; B Stobbe; K A Lehmann
Journal:  Schmerz       Date:  1990-12       Impact factor: 1.107

9.  Evaluation of patient-controlled analgesia (PCA) versus PCA plus continuous infusion in postoperative cancer patients.

Authors:  L A Hansen; M A Noyes; M E Lehman
Journal:  J Pain Symptom Manage       Date:  1991-01       Impact factor: 3.612

10.  Pain in far-advanced cancer.

Authors:  Robert G Twycross; Sarah Fairfield
Journal:  Pain       Date:  1982-11       Impact factor: 6.961

View more
  4 in total

1.  [Under what conditions is subcutaneous administration of fluid indicated].

Authors:  C Bausewein
Journal:  Internist (Berl)       Date:  2007-04       Impact factor: 0.743

2.  Subcutaneous or intravenous opioid administration by patient-controlled analgesia in cancer pain: a systematic literature review.

Authors:  Lisa Nijland; Pia Schmidt; Michael Frosch; Julia Wager; Bettina Hübner-Möhler; Ross Drake; Boris Zernikow
Journal:  Support Care Cancer       Date:  2018-07-28       Impact factor: 3.603

3.  [Continuous subcutaneous buprenorphine application in the treatment of cancer pain.].

Authors:  I Gralow; W F von Hornstein; E Schleyer; W Hiddemann
Journal:  Schmerz       Date:  1995-05       Impact factor: 1.107

4.  [Patient-controlled analgesia in outpatients with severe cancer pain.].

Authors:  M Herbst; H Goeke
Journal:  Schmerz       Date:  1995-03       Impact factor: 1.107

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.